Actively Recruiting
Multicenter Phase II Study of Tarlatamab Treatment in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer and ECOG Performance Status 2
Led by ETOP IBCSG Partners Foundation · Updated on 2026-09-21
48
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer ES-SCLC who have an ECOG Performance Status of 2 and have previously received only one line of platinum-etoposide chemotherapy combined with immune-checkpoint inhibition. This international, multicenter Phase II trial aims to measure the 12-month overall survival rate in this patient group whose disease has progressed. The study focuses on treatment options for patients with this advanced lung cancer subtype and limited prior therapy. Participants receive tarlatamab through an intravenous infusion starting with 1 mg on day 1, followed by 10 mg on days 8 and 15 of the first cycle, then 10 mg every two weeks thereafter. Treatment continues until disease progression according to RECIST v1.1 criteria, unacceptable side effects, or patient choice. This single-arm trial monitors patients receiving this drug regimen to assess its effects over time. During the study, participants will be closely monitored for overall survival, objective response rate, duration of response, disease control rate, progression-free survival, and the incidence and severity of any adverse events. These outcomes will be assessed for up to approximately 41 months from enrollment. Patients will undergo regular evaluations including clinical assessments and safety monitoring throughout their participation, which may last until disease progression or other study endpoints.
CONDITIONS
Brief Title
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Research Team
H
Heidi Roschitzki, PhD
S
Susanne Roux
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here